Agusti, A, De Stefano, G, Levi, A, Munoz, X, Romero-Mesones, C, Sibila, O, Lopez-Giraldo, A, Moral, VP, Curto, E, Echazarreta, AL, Marquez, SE, Pascual-Guardia, S, Santos, S, Marin, A, Valdes, L, Saldarini, F, Salgado, C, Casanovas, G, Varea, S, Rios, J, Faner, R. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. EUROPEAN RESPIRATORY JOURNAL. 2022; 59(3)DOI:10.1183/13993003.03036-2021. PMID:35144989. IF:24.300(Q1/1D).

Podzamczer, D, Mican, R, Tiraboschi, J, Portilla, J, Domingo, P, Llibre, JM, Ribera, E, Vivancos, MJ, Morano, L, Masia, M, Gomez, C, Fanjul, F, Payeras, A, Inciarte, A, Estrada, V, Rivero, A, Castro, A, Bernal, E, Vinuesa, D, Knobel, H, Troya, J, Macias, J, Montero, M, Sanz, J, Navarro-Alcaraz, A, Caicedo, A, Fernandez, G, Martinez, E, Moreno, S. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3)DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4.200(Q2/4D).

Garcia-Alfonso, P, Saiz-Rodriguez, M, Mondejar, R, Salazar, J, Paez, D, Borobia, AM, Safont, MJ, Garcia-Garcia, I, Colomer, R, Garcia-Gonzalez, X, Herrero, MJ, Lopez-Fernandez, LA, Abad-Santos, F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 2022; 24(3)DOI:10.1007/s12094-021-02708-4. PMID:34773566. IF:3.400(Q3/6D).

Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology. 2022; 18(8)DOI:10.2217/fon-2021-1286. PMID:35073733. IF:3.300(Q3/6D).

Sanchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, Carballal, S, Rodriguez-Alonso, L, Cajal, TRY, Llort, G, Pinol, V, Lopez-Fernandez, A, Salces, I, Pico, MD, Rivas, L, Bujanda, L, Garzon, M, Pizarro, A, de Castro, EM, Lopez-Arias, MJ, Poves, C, Garau, C, Rodriguez-Alcalde, D, Herraiz, M, Alvarez-Urrutia, C, Dacal, A, Carrillo-Palau, M, Cid, L, Ponce, M, Barreiro-Alonso, E, Saperas, E, Aguirre, E, Romero, C, Bastiaansen, B, Gonzalez-Acosta, M, Morales-Romero, B, Ocana, T, Rivero-Sanchez, L, Jung, G, Bessa, X, Cubiella, J, Jover, R, Rodriguez-Moranta, F, Balmana, J, Brunet, J, Castells, A, Dekker, E, Capella, G, Serra-Burriel, M, Moreira, L, Pellise, M, Balaguer, F. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology. 2022; 20(3)DOI:10.1016/j.cgh.2020.11.002. PMID:33157315. IF:12.600(Q1/1D).

Wu, YL, John, T, Grohe, C, Majem, M, Goldman, JW, Kim, SW, Kato, T, Laktionov, K, Vu, HV, Wang, ZJ, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Atasoy, A, Herbst, RS, Tsuboi, M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2022; 17(3)DOI:10.1016/j.jtho.2021.10.014. PMID:34740861. IF:20.400(Q1/1D).